A misrouted pallet of tablets is a stock problem. A misrouted bag of apheresis material is a patient problem, because there is no second batch, and the patient may already be part-way through a conditioning regimen timed around a delivery date that has now passed.

That single difference drives almost everything unusual about cell and gene therapy logistics. Conventional pharmaceutical distribution is built on fungibility: batches of thousands of packs, safety stock in the network, and the option to send a replacement. Autologous cell therapy has none of those. The starting material came from one named patient, the finished product goes back to that same patient, and the supply chain has to hold an unbroken link between the two.

This article maps the structural challenges and the controls that address them. Adjacent articles go deeper on ATMP provider capability, cryogenic storage, chain of identity, GDP differences and partner selection, so the treatment here is deliberately broad.

What makes cell and gene therapy logistics structurally different

Six characteristics separate this work from standard cold chain distribution.

There is no replacement batch. A failed shipment is a clinical event, not an inventory event. It may cost the patient a treatment window that cannot be rescheduled easily, or at all.

Batch sizes are tiny and unit values are enormous. A shipper may carry a single dose. The economics of redundancy change completely when one consignment is worth more than the entire fleet of shippers protecting it.

Shelf life can be measured in hours. Fresh, non-cryopreserved products may have viability windows of 24 to 72 hours from collection or from thaw. Cryopreserved products relieve the time pressure at the cost of a much harder temperature requirement.

Scheduling is coupled to a patient's clinical condition. Manufacturing slots, courier bookings, treatment centre capacity, pharmacy preparation and the patient's lymphodepletion schedule all have to line up. A change in the patient's condition can move everything downstream at short notice.

Human material crosses borders. Starting material and finished product are frequently shipped internationally, which brings import and export licensing, customs classification, human material documentation and biological substance transport rules into scope alongside medicines regulation.

The data burden is heavy. Every handover, temperature reading, location scan and identity check has to be recorded and retained, and traceability records for advanced therapy medicinal products carry long retention obligations.

The vein-to-vein loop

For autologous therapies the supply chain forms a closed loop rather than a line.

1. Apheresis collection at a qualified treatment centre, with the patient identifiers assigned to the material at the point of collection.
2. Preparation and shipment to manufacture, either fresh within a short window or after cryopreservation, typically in a dry vapour shipper.
3. Receipt and manufacture, including transduction or modification, expansion and formulation.
4. Quality control and QP certification, covering sterility, identity, potency and purity testing before release.
5. Return shipment to the treatment centre, usually cryopreserved.
6. Storage at the treatment centre, then thaw and infusion at a scheduled slot.

Every arrow between those steps is a chain of custody handover and a point at which identity can be broken. A conventional supply chain has perhaps three or four custody transfers between manufacture and patient. A vein-to-vein loop can have a dozen, several of them involving hospital staff who are not logistics professionals and who are working to a clinical rather than a distribution timetable.

Autologous versus allogeneic

Allogeneic products are made from donor material and yield multiple doses per batch. The inventory model is closer to conventional biologics: forecastable demand, doses held in stock, a failed shipment that is a cost and supply event rather than automatically a patient event.

The differences that remain are still significant. Donor traceability obligations apply, cryogenic storage and dry vapour transport are still the norm, and the release and import steps are the same. What changes is the tolerance for failure and the ability to plan. Allogeneic programmes can build buffer stock at regional depots; autologous programmes cannot, and must instead build redundancy into routes, equipment and time.

The controls that actually work

Orchestration and scheduling systems

The single most valuable investment in cell and gene therapy logistics is a scheduling system that holds the whole loop in one place: collection slot, manufacturing slot, courier bookings, release forecast and infusion date, with the dependencies between them made explicit. Managing this across email and spreadsheets works until the first change of date, then it does not.

Redundancy in shippers and routes

Plan the second shipper before you need it. That means pre-positioned qualified dry vapour shippers, at least two viable routings for each lane, and a documented decision on what happens if a flight is cancelled, an airport closes or a border control holds a consignment. Shipper hold times should be specified with genuine margin, not to the exact planned transit.

Courier and lane qualification

Couriers handling this material should be qualified as suppliers under a documented process, with defined competencies: temperature-controlled handling, hand-carry options where used, out-of-hours contact, contingency authority and the ability to produce a full custody record. Lanes should be qualified with test shipments before live use, and requalified when the routing changes.

Temperature and location telemetry

Continuous monitoring with real-time location and temperature reporting turns an unrecoverable failure into a manageable one. An alert that a shipper is warming while it is still on the ground allows intervention. A data logger read on arrival only tells you what you already lost. Alarms need a named responder with authority to act at any hour.

Chain of identity and chain of custody discipline

Chain of identity is the unbroken link between patient, starting material and finished product. Chain of custody is the documented control of the physical material at every moment. They are different controls and both are required. In practice this means unique identifiers applied at collection, verified at every handover by scan rather than by eye, and reconciled at infusion against the patient's own identifiers.

Rehearsal and dry runs

Run the lane with a dummy consignment before the first patient. Dry runs expose the things process maps do not: the treatment centre goods-in that closes at 17:00, the loading bay a shipper does not fit through, the customs broker who has never seen a human material declaration. Repeat them when a site, courier or route changes.

Key takeaways

• Dry runs on every new lane, site and courier find the failure modes that process documents miss.
• In autologous cell and gene therapy logistics there is no replacement batch, so a shipment failure is a patient event rather than a stock event.
• The vein-to-vein loop creates far more custody handovers than a conventional supply chain, and each one is a point where identity can break.
• Allogeneic products allow buffer stock and forecasting; autologous programmes must build redundancy into shippers, routes and time instead.
• Real-time temperature and location telemetry with an empowered out-of-hours responder converts many potential losses into recoverable events.

Talk to Central Pharma about cell and gene therapy logistics

Central Pharma supports cell and gene therapy programmes from its 267,000 sq ft Bedford site under MHRA MIA and WDA(H) authorisations, with temperature-monitored and controlled warehousing across ambient, +2°C to +8°C and −20°C, GDP-compliant handling, kitting, labelling and secondary packing, site of importation status, three Qualified Persons and QP release to more than 60 countries, all wrapped in dedicated project management. Where a programme requires deep-cryogenic storage or transport, those steps are coordinated through specialist approved partners. Get in touch to discuss your programme.

To stay informed on our latest thinking and technology developments, follow us on LinkedIn.

Contact Us Today

View all news